# A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

> **NCT03600883** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 713 (actual)

## Conditions studied

- KRAS p.G12C Mutant Advanced Solid Tumors

## Interventions

- **DRUG:** sotorasib
- **DRUG:** Anti PD-1/L1
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT03600883
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-27
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 713 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03600883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03600883, "A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03600883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*